Complex Mixtures

Mixtures of many components in inexact proportions, usually natural, such as PLANT EXTRACTS; VENOMS; and MANURE. These are distinguished from DRUG COMBINATIONS which have only a few components in definite proportions.
DrugDrug NameDrug Indication
DB00032MenotropinsFor the treatment of female infertility
DB00042Botulinum Toxin Type BFor the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
DB00085PancrelipaseThe use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy. This therapy is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it.[A32721, A32736] Pancreatic diseases are associated with the deterioration of pancreatic parenchyma and of the dual physiological functions of the pancreas. Once established, pancreatic insufficiency results in malnutrition, weight loss, and steatorrhea.[A32723]
DB00094UrofollitropinFor treatment of female infertility
DB00098Antithymocyte immunoglobulin (rabbit)For prevention of renal transplant rejection
DB00908QuinidineFor the treatment of ventricular pre-excitation and cardiac dysrhythmias
DB00965Ethiodized oilFor use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is 131-I. It is also used in follow-up imaging for chemoembolization.
DB01445BufotenineNot Available
DB01744CamphorNot Available
DB02955Ricinoleic AcidNot Available
DB04660Choline alfoscerateNot Available
DB04914G17DTIntended for the treatment of various forms of cancer.
DB05051BZL101Investigated for use/treatment in breast cancer.
DB05099AncrodAncrod is indicated for the treatment of deep vein thrombosis (DVT), central retinal branch vein thrombosis, pripaism, pulmonary hypertension of embolic origin, embolism after insertion of prosthetic cardiac valves, rethrombosis after thrombolytic therapy, rethrombosis after vascular surgery, and prevention of DVT after repair of a fractured neck of a femur.
DB05322INGN 201Investigated for use/treatment in bladder cancer, brain cancer, breast cancer, esophageal cancer, head and neck cancer, lung cancer, oral cavity cancer, ovarian cancer, and prostate cancer.
DB05325INGN 225Investigated for use/treatment in breast cancer, head and neck cancer, and lung cancer.
DB05374RindopepimutInvestigated for use/treatment in brain cancer.
DB05387AE-941Investigated for use/treatment in kidney cancer, lung cancer, macular degeneration, multiple myeloma, prostate cancer, and psoriasis and psoriatic disorders.
DB05440SRP 299Investigated for use/treatment in asthma, atopic dermatitis, and pediatric atopic dermatitis indications.
DB05445TA-NICInvestigated for use/treatment in tobacco dependence.
DB05767AndrographolideInvestigated for use/treatment in ulcerative colitis.
DB05771LLL-3348Investigated for use/treatment in psoriasis and psoriatic disorders.
DB05942GI-5005Investigated for use/treatment in hepatitis (viral, C).
DB06283ZiconotideNot Available
DB06415CalfactantCalfactant is indicated for prophylaxis therapy to prevent respiratory distress syndrome (RDS) in premature infants <29 weeks of gestational age with low lung surfactant and at high risk for RDS. Calfactant therapy is also indicated for the treatment of respiratory distress syndrome in infants 72 hours or less of age with RDS confirmed by clinical and radiologic findings and requiring endotracheal intubation.
DB06584TG4010Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
DB06688Sipuleucel-TSipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
DB06761BeractantBeractant is indicated for prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants.
DB08839SerotoninNot Available
DB09005BatroxobinNo approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.
DB09094Podophyllin25% podophyllin (in benzoin tincture) is indicated for the removal of soft genital (venereal) warts (condylomata acuminata).
DB09113Poractant alfaPoractant alfa is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants.
DB09312Antilymphocyte immunoglobulin (horse)For prevention of renal transplant rejection and for the treatment of aplastic anemia.
DB09422Soybean oilIndicated for parenteral nutrition as a source of calories and essential fatty acids when oral or enteral nutrition is not possible, insufficient, or contraindicated.
DB09446Safflower oilNo approved therapeutic indications.
DB09507FerumoxsilNot Available
DB09543Methyl salicylateOintments or liniments containing methyl salicylate are applied topically as counter irritant for relief of acute pain associated with lumbago,sciatica and rheumatic conditions. Local analgesics for human and veterinary medicine.
DB09567Olive oilFor use in adults as a source of calories and fatty acids in total parenteral nutrition [FDA Label]. Sometimes used as an additive in cosmetic products.
DB10283Rabies virus inactivated antigen, ANot Available
DB10318Varicella Zoster Vaccine (Live/Attenuated)Zostavax vaccine is indicated for the prevention of herpes zoster (shingles) in immunocompetent adults aged 50 years and older. Varivax vaccine is indicated for active immunization for the prevention of varicella in individuals 12 months of age and older.
DB10345House dustNot Available
DB10535Karaya gumNot Available
DB10583Clostridium tetani toxoid antigen (formaldehyde inactivated)Not Available
DB10584Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)Not Available
DB10667TragacanthNot Available
DB10852CarobNot Available
DB11082Coal tarRelieving itching, irritation, redness, dryness, scaling, and flaking of the skin caused by psoriasis, seborrhea, or eczema.
DB11097Plantago seedIndications include the treatment of patients needing a high fibre regime, perhaps for: (a) the relief of constipation, including constipation in pregnancy and the maintenance of regularity; (b) the management of bowel function in patients with colostomy, ileostomy, hemorrhoids, anal fissure, chronic diarrhea with diverticular disease, irritable bowel syndrome, and ulcerative colitis [L1865].
DB11113Castor oilIndicated for over-the-counter use as a laxative for oral use and as a soothing agent for topical use on skin and hair.
DB11120TurpentineTurpentine has been used experimentally in a bath for the treatment of disseminated sclerosis and sexual dysfunction. It also has been studied for its antibacterial activity and inhibition of osteoclast activity. Turpentine is utilized in experimental models of inflammation to induce a systemic inflammatory immune response in animals.
DB11130OpiumOpium and its derivatives are the most commonly used medications for the treatment of acute and chronic pain. Opium and its alkaloid-derivatives can also be used as tranquilizers, antitussives and in the treatment of diarrhea.[T138] The direct use of opium is not common nowadays but the use of some of its derivatives such as morphine and codeine, as well as the use of a tincture of opium for severe diarrhea can be seen in medical practice.[T139] Illegal use of opium has been registered to be for both recreational and medicinal purposes.[A32182]
DB11131Capsicum oleoresinIndicated for the temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains and sprains.
DB11132Silicon dioxideNot Available
DB11158PectinPectin is used in food as a gelling agent and stabilizer. As a medical drug, it has obtained a great interest in its potential use as a source of dietary fiber, lipid, cholesterol, serum glucose and insulin level lowering effect, gastric emptying delay.[A32327] Some recent studies have researched the possibility of using pectin for the formation of nanoparticles as a delivery vehicle of drugs.[A32331]
DB11165RosinNot Available
DB11172Sesame oilNot Available
DB11198Peppermint oilIndicated for the over-the-counter use for: -the symptomatic relief of minor spasms of the gastrointestinal tract, flatulence and abdominal pain, especially in patients with irritable bowel syndrome. -the temporary relief of itching associated with insect bites, eczema, minor burn, sunburn, minor skin irritations, minor cuts, scrapes, atopic dermatitis and other skin disorders. -the temporary symptomatic relief of mild joint and muscle pain as a local topical analgesic. -the temporary relief of tension-type headache.
DB11218Tea tree oilIndicated for topical use to help protect against infection in minor cuts, scrapes, and burns. No FDA-approved therapeutic indications.
DB11222Benzoin resinIndicated for mild antisepsis of skin, cuts, and abrasions.
DB11223Tolu balsamNot Available
DB11238Borage oilNot Available
DB11293Rice bran oilNot Available
DB11338Clove oilClove oil is primarily indicated in conditions like colic, flatulence, and toothache [L2849].
DB11357Linseed oilNot Available
DB11358Evening primrose oilEvening primrose oil is used as part of over-the-counter dietary supplements.[L1113] It is also used for the treatment of systemic inflammatory diseases and for women's health conditions such as cyclical mastalgia. These indications do not have sufficient evidence of their effectiveness. It was used for the treatment of atopic dermatitis in the United Kingdom but it is currently withdrawn due to lack of evidence of effectiveness.[A33131]
DB11365SennosidesFor the over the counter treatment of constipation[FDA Label][L771].
DB11482Balsam of PeruBalsam of Peru is found in diverse cosmetics and perfumes as well as a flavoring agent in cough syrups, lozenges, chewing gum, and candies.[F117] As a medical agent, balsam of Peru is used in the local treatment of burns and wounds as an antiseptic.[A27160] It is also used as an expectorant, heart stimulant to increase blood pressure and as a parasiticide.[T221]
DB11621Human Varicella-Zoster Immune GlobulinIndicated for preventing and reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals within 4 days of exposure to varicella zoster virus.
DB11724BombesinNot Available
DB11777CenderitideNot Available
DB11890CilengitideNot Available
DB11980Carbon BlackNot Available
DB12568TecemotideNot Available
DB12684AviscumineNot Available
DB12768BCG vaccineNot Available
DB13116NorfluraneNot Available
DB13153LevomenolLevomenol has been known to elicit a number of potentially beneficial pharmacological effects, including anti-irritant, anti-inflammatory, and anti-microbial actions. Bisabolol is also demonstrated to enhance the percutaneous absorption of certain molecules
DB13293IpecacIpecac is indicated as an emetic agent for the induction of vomiting in poisoning victims who ingested systemic poison in order to prevent absorption of the chemicals through the gastrointestinal tract. In low doses, ipecac was also used as an expectorant.[L2753] Reports have suggested that ipecac was vastly used in patients with eating disorders to produce vomiting.[T49]
DB13446Guar gumNot Available
DB13964Peanut oilPeanut oil is widely used in food and it is even the component for the adulteration of olive oil.[T41] It is used in over-the-counter ear drops to help lubricate the ear wax.[F124] It was also used as an ingredient in cleansing soaps, in emollient cream preparations or in laxatives.[L2892, F125] Peanut oil is also used usually to solubilize drugs with poor water solubility as part of the oral formulation.[T224] When orally administered, peanut oil has as well been researched and used to prevent heart diseases and lower cholesterol levels as well as to aid in weight loss and decrease appetite.[L2897]
DB140105-methoxy-N,N-dimethyltryptamineNot Available
DB14011NabiximolsIn Canada, Sativex has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy. Sativex has also received a Notice of Compliance with Conditions (NOC/c) for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis (MS) and as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. Marketing authorisations with conditions reflect the promising nature of the clinical evidence and the need for confirmatory studies to verify the clinical benefit. Patients should be advised of the conditional nature of the authorizations with conditions.
DB14022Typhoid vaccineNot Available
DB14248Bos taurus gallstoneNot Available
DB14276TurmericNot Available
DB14304Panax notoginseng rootNot Available
DB14307Green tea leafNot Available
DB14309Meadowfoam seed oilNot Available
DB14310Argan oilNot Available
DB14316Tangerine peelNot Available
DB14322Coconut oilNot Available
DB14326AmberNot Available
DB14329Sunflower oilNot Available
DB14333Nelumbo nucifera flowerNot Available
DB14335Bergamot oilNot Available
DB14336Angelica sinensis rootNot Available
DB14345Forsythia suspensa fruitNot Available
DB14360Saw palmettoNot Available
DB14364Scutellaria baicalensis rootNot Available
DB14377Palm oilNot Available
DB14565Sophora flavescens rootNot Available
DB14566Lavender oilNot Available
DB14585Plantago ovata seedNot Available
DB05724alpha-Conotoxin VC 1.1Investigated for use/treatment in pain (acute or chronic).
DB07715EmodinNot Available
DB10394Phleum pratense pollenNot Available
DB10805Yellow Fever VaccineYellow Fever Vaccine is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories: 1. Persons Living in or Traveling to Endemic Areas: While the actual risk for contracting yellow fever during travel is probably low, variability of itineraries, behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area. Greater risk is associated with living in or traveling to areas of South America and Africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone. 2. Persons Travelling Internationally Through Countries with Yellow Fever: Some countries require an individual to have a valid International Certificate of Vaccination or Prophylaxis (ICVP) if the individual has been in countries either known or thought to harbor yellow fever virus. The certificate becomes valid 10 days after vaccination with Yellow Fever Vaccine. 3. Laboratory Personnel: Laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect contact or by aerosols.
DB10989Hepatitis A VaccineHepatitis A vaccine is indicated for active immunization against disease caused by hepatitis A virus (HAV). It is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV. HAVRIX® will not prevent hepatitis infection caused by other agents such as hepatitis B virus, hepatitis C virus, hepatitis E virus or other pathogens known to infect the liver. In areas of low to intermediate prevalence of hepatitis A, immunization with HAVRIX® is particularly recommended in subjects who are, or will be, at increased risk of infection such as: * Travelers: Persons traveling to areas where the prevalence of hepatitis A is high. These areas include Africa, Asia, the Mediterranean basin, the Middle East, Central and South America. * Armed Forces: Armed Forces personnel who travel to higher endemicity areas or to areas where hygiene is poor have an increased risk of HAV infection. Active immunization is indicated for these individuals. * Persons for whom Hepatitis A is an Occupational Hazard: These include employees in day-care centres, nursing, medical and paramedical personnel in hospitals and institutions, especially gastroenterology and pediatric units, sewage workers, and food handlers, among others. * Persons for whom there is an Increased Risk of Transmission of Hepatitis A: e.g. homosexuals, persons with multiple sexual partners, abusers of injectable drugs, hemophiliac patients. * Contacts of Infected Persons: Since virus shedding of infected persons may occur for a prolonged period, active immunization of close contacts is recommended. * Specific Population Groups known to have Higher Incidence of Hepatitis A: e.g. North American Indians, Inuits, recognized community-wide HAV epidemics. * Subjects with chronic liver disease or who are at risk of developing chronic liver disease e.g. Hepatitis B (HB) and Hepatitis C (HC) chronic carriers and alcohol abusers.
DB11627Hepatitis B Vaccine (Recombinant)Active immunization against hepatitis B virus infection. The vaccine will not protect against infection caused by hepatitis A and non-A non-B hepatitis viruses. As hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection or carrier state, it can be expected that hepatitis D will also be prevented by vaccination with hepatitis B virus vaccine. The vaccine can be administered at any age from birth onwards. It may be used to start a primary course of vaccination or as a booster dose. It may also be used to complete a primary course of vaccination started with plasma-derived or yeast-derived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasma-derived or yeast-derived vaccines. In areas of low prevalence of hepatitis B, vaccination is strongly recommended in subjects who are at increased risk of infection. These include the following groups: * Health professionals: physicians and surgeons; oral surgeons and dentists; nurses, dental nurses, dental hygienists, podiatrists; IV teams and operating room personnel; paramedical personnel in close contact with patients; staff in hemodialysis, nephrology, hepatology, hematology and oncology units; laboratory personnel handling blood and other clinical specimens; blood bank and plasma fractionation workers; pathologists and morgue attendants; cleaning staff who handle waste in hospitals; emergency and first aid workers; ambulance staff; dental, medical and nursing students. * Patients: patients receiving frequent blood transfusion or clotting factor concentrates, such as those in oncology units and those with thalassemia, sickle-cell anemia, cirrhosis, hemophilia, etc.; patients on hemodialysis; patients with type 2 diabetes. * Personnel and residents of institutions: persons with frequent and/or close contacts with high-risk groups; prisoners and prison staff; residents and staff of institutions for the developmentally challenged (those who are in contact with aggressive biting residents being at highest risk). * Persons at increased risk due to their sexual practices: males having sexual contact with other males; others with multiple sexual partners or with a recent history of sexually transmitted disease. * Persons who use injectable drugs illicitly. * Travellers to areas of high endemicity and their close contacts. * Household contacts of any of the above groups and of patients with acute or chronic hepatitis B infection. * Infants born of HBsAg-positive mothers. * Chronic Liver Disease (CLD): subjects with chronic liver disease; subjects at risk of developing CLD (e.g. Hepatitis C virus carriers, persons who abuse alcohol). * Others: police; fire fighters; armed forces personnel; morticians and embalmers; those who through their work or personal lifestyle may be exposed to the hepatitis B virus. * In areas of both low and high prevalence, vaccination should be offered to all young children and neonates at risk, as well as to adult high risk groups.
DB01381Ginkgo bilobaAppears to be effective in: alleviating age-related memory impairment in some elderly people with mild to moderate age-related memory or cognitive impairment; improving cognitive function in healthy young to middle-aged people; improving symptoms of Alzheimer's, vascular or mixed dementia; improving damage to the visual field in patients with normal tension glaucoma; decreasing the number of painful attacks in patients with Raynaud's syndrome; and may improve symptoms of vertigo and dizziness in some patients.
DB06400VitespenInvestigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.
DB14771Polyacrylamide (crosslinked; 2 mole percent bisacrylamide)Not Available
DB15094AnfibatideNot Available
DB15210ChlorotoxinNot Available
DB15259VB-201Not Available
DB15274Pertussis vaccineNot Available
DB15375TozuleristideNot Available
DB15461Yersinia pestis 195/p antigen (formaldehyde inactivated)Not Available
DrugDrug NameTargetType
DB00032MenotropinsFollicle-stimulating hormone receptortarget
DB00032MenotropinsLutropin-choriogonadotropic hormone receptortarget
DB00042Botulinum Toxin Type BVesicle-associated membrane protein 1target
DB00042Botulinum Toxin Type BVesicle-associated membrane protein 2target
DB00042Botulinum Toxin Type BSynaptotagmin-2target
DB00085PancrelipaseDietary fattarget
DB00085PancrelipaseDietary proteintarget
DB00085PancrelipaseDietary starchtarget
DB00094UrofollitropinFollicle-stimulating hormone receptortarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
DB00098Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
DB00098Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
DB00098Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
DB00908QuinidineSodium channel protein type 5 subunit alphatarget
DB00908QuinidineAlpha-1-acid glycoprotein 1carrier
DB00908QuinidinePotassium voltage-gated channel subfamily H member 2target
DB00908QuinidinePotassium channel subfamily K member 1target
DB00908QuinidinePotassium channel subfamily K member 6target
DB00908QuinidineCytochrome P450 1A2enzyme
DB00908QuinidineCytochrome P450 2E1enzyme
DB00908QuinidineCytochrome P450 1A1enzyme
DB00908QuinidineCytochrome P450 2D6enzyme
DB00908QuinidineCytochrome P450 3A4enzyme
DB00908QuinidineCytochrome P450 3A7enzyme
DB00908QuinidineSolute carrier family 22 member 2transporter
DB00908QuinidineSolute carrier family 22 member 1transporter
DB00908QuinidineSolute carrier family 22 member 5transporter
DB00908QuinidineMultidrug resistance protein 1transporter
DB00908QuinidineSolute carrier organic anion transporter family member 1A2transporter
DB00908QuinidineSolute carrier family 22 member 8transporter
DB00908QuinidineCanalicular multispecific organic anion transporter 1transporter
DB00908QuinidineSolute carrier family 22 member 4transporter
DB00908QuinidineSolute carrier organic anion transporter family member 1B1transporter
DB00908QuinidineCytochrome P450 2B6enzyme
DB00908QuinidineCytochrome P450 2C9enzyme
DB00908QuinidineAlpha-1A adrenergic receptortarget
DB00908QuinidineAlpha-1B adrenergic receptortarget
DB00908QuinidineAlpha-1D adrenergic receptortarget
DB00908QuinidineBile salt export pumptransporter
DB00908QuinidineCytochrome P450 2C8enzyme
DB01445BufotenineAmine oxidase [flavin-containing] Aenzyme
DB01445BufotenineAmine oxidase [flavin-containing] Benzyme
DB01744CamphorCamphor 5-monooxygenasetarget
DB01744CamphorTransient receptor potential cation channel subfamily V member 1target
DB01744CamphorTransient receptor potential cation channel subfamily V member 3target
DB01744CamphorTransient receptor potential cation channel subfamily A member 1target
DB01744CamphorTransient receptor potential cation channel subfamily M member 8target
DB02955Ricinoleic AcidCannabinoid receptor 1target
DB02955Ricinoleic AcidCannabinoid receptor 2target
DB02955Ricinoleic AcidTransient receptor potential cation channel subfamily V member 1target
DB04660Choline alfoscerateGanglioside GM2 activatortarget
DB05099AncrodFibrinogen alpha chaintarget
DB05374RindopepimutEpidermal growth factor receptortarget
DB05387AE-94172 kDa type IV collagenasetarget
DB05387AE-941Matrix metalloproteinase-9target
DB05387AE-941Macrophage metalloelastasetarget
DB05767AndrographolideTumor necrosis factortarget
DB05767AndrographolideInterleukin-1 betatarget
DB05767AndrographolideInterleukin-6target
DB05767AndrographolideNuclear factor NF-kappa-B p100 subunittarget
DB05767AndrographolideNuclear factor NF-kappa-B p105 subunittarget
DB05771LLL-3348Interleukin-10target
DB06283ZiconotideCytochrome P450 3A4enzyme
DB06584TG4010Mucin-1target
DB06584TG4010Interleukin-2target
DB06688Sipuleucel-TProstatic acid phosphatasetarget
DB08839SerotoninSolute carrier family 22 member 2transporter
DB08839SerotoninSodium-dependent serotonin transportertarget
DB08839Serotonin5-hydroxytryptamine receptor 2Atarget
DB08839Serotonin5-hydroxytryptamine receptor 3Atarget
DB08839Serotonin5-hydroxytryptamine receptor 3Btarget
DB08839SerotoninSynaptic vesicular amine transportertarget
DB09422Soybean oilPeroxisome proliferator-activated receptor alphatarget
DB11113Castor oilProstaglandin E2 receptor EP3 subtypetarget
DB11113Castor oilProstaglandin E2 receptor EP4 subtypetarget
DB11120TurpentineMitogen-activated protein kinase 1target
DB11130OpiumDelta-type opioid receptortarget
DB11130OpiumKappa-type opioid receptortarget
DB11130OpiumMu-type opioid receptortarget
DB11130OpiumSerum albumincarrier
DB11130OpiumBeta-2-microglobulincarrier
DB11130OpiumCytochrome P450 2D6enzyme
DB11130OpiumCytochrome P450 3A4enzyme
DB11131Capsicum oleoresinTransient receptor potential cation channel subfamily V member 1target
DB11132Silicon dioxideMacrophage receptor MARCOtarget
DB11198Peppermint oilCytochrome P450 1A2enzyme
DB11198Peppermint oilCytochrome P450 3A4enzyme
DB11338Clove oilVascular cell adhesion protein 1target
DB11338Clove oilC-X-C motif chemokine 10target
DB11338Clove oilCollagen alpha-1(I) chaintarget
DB11338Clove oilGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB11358Evening primrose oilElongation of very long chain fatty acids protein 5enzyme
DB11358Evening primrose oilFatty acid desaturase 1enzyme
DB11358Evening primrose oilFatty acid desaturase 2enzyme
DB11365SennosidesReverse transcriptase/RNaseHtarget
DB11365SennosidesAquaporin-3target
DB13153LevomenolSolute carrier organic anion transporter family member 1B1transporter
DB13153LevomenolSolute carrier organic anion transporter family member 1B3transporter
DB13293IpecacCytochrome P450 2D6enzyme
DB13293IpecacCytochrome P450 3A4enzyme
DB140105-methoxy-N,N-dimethyltryptamine5-hydroxytryptamine receptor 1Atarget
DB140105-methoxy-N,N-dimethyltryptamine5-hydroxytryptamine receptor 2Atarget
DB140105-methoxy-N,N-dimethyltryptamineCytochrome P450 2D6enzyme
DB14011NabiximolsCannabinoid receptor 1target
DB14011NabiximolsCannabinoid receptor 2target
DB14011NabiximolsG-protein coupled receptor 12target
DB14011NabiximolsCytochrome P450 2C9enzyme
DB14011NabiximolsCytochrome P450 2C19enzyme
DB14011NabiximolsCytochrome P450 2D6enzyme
DB14011NabiximolsCytochrome P450 3A4enzyme
DB14011NabiximolsGlycine receptor subunit alpha-1target
DB14011NabiximolsGlycine receptor (alpha-1/beta)target
DB14011NabiximolsGlycine receptor subunit alpha-3target
DB14011NabiximolsN-arachidonyl glycine receptortarget
DB14011NabiximolsG-protein coupled receptor 55target
DB14011Nabiximols5-hydroxytryptamine receptor 1Atarget
DB14011Nabiximols5-hydroxytryptamine receptor 2Atarget
DB14011NabiximolsNeuronal acetylcholine receptor subunit alpha-7target
DB14011NabiximolsDelta-type opioid receptortarget
DB14011NabiximolsMu-type opioid receptortarget
DB14011NabiximolsPeroxisome proliferator-activated receptor gammatarget
DB14011NabiximolsCytochrome P450 3A5enzyme
DB14011NabiximolsAcetyl-CoA acetyltransferase, mitochondrialenzyme
DB14011NabiximolsArylalkylamine N-acetyltransferaseenzyme
DB14011NabiximolsCatalaseenzyme
DB14011NabiximolsProstaglandin G/H synthase 1enzyme
DB14011NabiximolsProstaglandin G/H synthase 2enzyme
DB14011NabiximolsCytochrome P450 3A7enzyme
DB14011NabiximolsCytochrome P450 1A1enzyme
DB14011NabiximolsCytochrome P450 1A2enzyme
DB14011NabiximolsCytochrome P450 1B1enzyme
DB14011NabiximolsSn1-specific diacylglycerol lipase alphaenzyme
DB14011NabiximolsFatty-acid amide hydrolase 1enzyme
DB14011NabiximolsGlutathione reductase, mitochondrialenzyme
DB14011NabiximolsGlutathione peroxidase 1enzyme
DB14011Nabiximols3-hydroxy-3-methylglutaryl-coenzyme A reductaseenzyme
DB14011NabiximolsIndoleamine 2,3-dioxygenase 1enzyme
DB14011NabiximolsArachidonate 5-lipoxygenaseenzyme
DB14011NabiximolsArachidonate 15-lipoxygenaseenzyme
DB14011NabiximolsN-acylethanolamine-hydrolyzing acid amidaseenzyme
DB14011NabiximolsQuinone oxidoreductaseenzyme
DB14011NabiximolsN-acyl-phosphatidylethanolamine-hydrolyzing phospholipase Denzyme
DB14011NabiximolsPhospholipase A2enzyme
DB14011NabiximolsSteroid 17-alpha-hydroxylase/17,20 lyaseenzyme
DB14011NabiximolsSuperoxide dismutase [Cu-Zn]enzyme
DB14011NabiximolsSphingomyelin phosphodiesteraseenzyme
DB14011NabiximolsMultidrug resistance-associated protein 1transporter
DB14011NabiximolsATP-binding cassette sub-family G member 2transporter
DB14011NabiximolsEquilibrative nucleoside transporter 1transporter
DB14011NabiximolsTransient receptor potential cation channel subfamily V member 1target
DB14011NabiximolsVoltage-dependent T-type calcium channel subunit alpha-1Gtarget
DB14011NabiximolsVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB14011NabiximolsVoltage-dependent T-type calcium channel subunit alpha-1Itarget
DB14011NabiximolsTransient receptor potential cation channel subfamily A member 1target
DB14011NabiximolsTransient receptor potential cation channel subfamily M member 8target
DB14011NabiximolsTransient receptor potential cation channel subfamily V member 2target
DB14011NabiximolsTransient receptor potential cation channel subfamily V member 3target
DB14011NabiximolsTransient receptor potential cation channel subfamily V member 4target
DB14011NabiximolsVoltage-dependent anion-selective channel protein 1target
DB07715EmodinCasein kinase II subunit alphatarget
DB07715EmodinPutative ketoacyl reductasetarget
DB07715Emodin3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZtarget
DB07715EmodinAryl hydrocarbon receptortarget
DB01381Ginkgo bilobaCytochrome P450 2C9enzyme
DB01381Ginkgo bilobaPhospholipase A2, membrane associatedtarget
DB01381Ginkgo bilobaSodium-dependent noradrenaline transportertarget
DB01381Ginkgo bilobaGlycine receptor subunit alpha-1target
DB01381Ginkgo bilobaGamma-aminobutyric acid receptor subunit alpha-1target
DB01381Ginkgo bilobaGamma-aminobutyric acid receptor subunit beta-2target
DB01381Ginkgo bilobaGamma-aminobutyric acid receptor subunit gamma-2target